FDA Committee Recommends Celebrex For Arthritis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Committee Recommends Celebrex For Arthritis

ST. LOUIS, MO -- Dec. 3, 1998 -- The United States Food and Drug Administration’s arthritis advisory committee has recommended the approval of Searle and Pfizer’s Celebrex(TM) (celecoxib) to treat patients with osteoarthritis and rheumatoid arthritis.

However, the same committee said it could not immediately decide on whether to recommend the drug Celebrex for use in acute pain management.

Celebrex is a member of a proposed new class of agents known as specific COX-2 inhibitors, which are designed to block the COX-2 enzyme activated in inflammation while sparing the activity of the COX-1 enzyme that protects the lining of the GI tract. The COX-1 enzyme also plays a role in blood clotting and kidney functions. Common side effects of NSAIDs, which are non-specific inhibitors of COX-1 and COX-2, include GI ulceration and bleeding, inhibition of platelet aggregation and interactions with other drugs.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities